Viking Therapeutics Inc. (VKTX)
Viking Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?
Since VKTX is devoid of marketed drugs, investors will focus on pipeline updates when it reports Q4 results next week.
Why this Weight-Loss Drug Stock Could Gain 200%
There are several potential challengers to Novo Nordisk and Eli Lilly's obesity drugs, and Jefferies analysts see one as particularly promising.
This Biotech Stock Soared 116% in 2024, but Is It a Buy in 2025?
One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs that's proven to be both efficacious and safe in clinical studies and in the real world. You might be familiar with the top sellers, such as Eli Lilly's Zepbound or Novo Nordisk's Wegovy -- they've made headlines as demand for them soared.
Viking Therapeutics, Inc. (VKTX) Increases Yet Falls Behind Market: What Investors Need to Know
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $32.87, denoting a +0.67% change from the preceding trading day.
What's next for Viking Therapeutics? Here's how the company can scale up.
Viking's obesity-drug program is progressing well. Now management is thinking about manufacturing tie-ups.
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug
The initiation of the phase 2 study is based on early-stage data, which show that patients who received VKTX's obesity pill lost up to 8.2% in body weight after 28 days.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
NEW YORK CITY, NY / ACCESSWIRE / January 6, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
1 Under-the-Radar Stock to Buy Before It Soars by 156%, According to Select Wall Street Analysts
In this video, I will cover the recent updates regarding Viking Therapeutics (VKTX 1.26%). Watch the short video to learn more, consider subscribing, and click the special offer link below.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
NEW YORK, NY / ACCESSWIRE / January 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ: VKTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Why Viking Therapeutics Stock Plummeted by 24% in December
Viking Therapeutics (VKTX 4.30%) didn't exactly capture investors' hearts in the final month of 2024. The biotech company's share price eroded by 24% in December, primarily on the back of a rival's aggressive move into a potentially very lucrative segment of the pharmaceutical market.
